金色化物Rk1通过激活氧酶增殖器激活受体来改善糖尿病患者的内皮功能
Lingchao Miao1, Yan Zhou1, Dechao Tan1,2
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China. annacheang@um.edu.mo.
银化物Rk1通过减少氧化应激减轻糖尿病的内皮功能障碍,从而改善糖尿病的内皮功能障碍. 这种传统中医药激活过氧体增殖器激活受体 (PPAR) /内皮氧化合成酶 (eNOS) 途径,提供血管保护.
科学领域:
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕纳克斯人参的成分金色化物Rk1具有已知的抗瘤和抗聚合性质.
- 它对内皮功能的影响,特别是在糖尿病中,仍然在很大程度上未被探索.
- 内皮功能障碍是糖尿病的一个关键并发症,导致心血管疾病.
研究的目的:
- 在糖尿病模型中研究金氏化物Rk1在改善内皮功能障碍方面的疗效.
- 阐明潜在的分子机制,重点是氧化应激和氧酶增殖器激活受体 (PPAR) 途径.
主要方法:
- 在体内:高脂肪饮食诱导的糖尿病小鼠接受了人参胺Rk1.1.的治疗.
- 活体:隔离的小鼠大动脉暴露于高葡萄糖和人参化物Rk1.1.
- 试验室内:以高葡萄糖刺激并用人参化物Rk1.1处理的初级大鼠大动脉内皮细胞 (RAECs).
- 对内皮依赖放松,氧化应激,PPAR异型和内皮氧化合成酶 (eNOS) 酸化的评估.
主要成果:
- 高葡萄糖和高脂肪饮食诱导了内皮功能障碍,增加了氧化应激,降低了PPAR和eNOS酸化.
- 在体内和体外模型中,丁胺Rk1治疗显著改善了内皮功能,并减少了氧化应激.
- 人参化物Rk1的保护作用被PPAR抗剂减弱,这表明该途径的参与.
结论:
- 金色化物Rk1有效地改善糖尿病患者内皮功能障碍.
- 该化合物通过激活PPAR/eNOS通路来抑制氧化应激来发挥其保护作用.
- 这项研究强调了人参化物Rk1作为糖尿病血管并发症的潜在治疗剂.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
相关概念视频
Insulin: The Receptor and Signaling Pathways
cAMP-dependent Protein Kinase Pathways
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Regulation of Angiogenesis and Blood Supply
